All In Biotech

Drug Trial Radar · NCT04152499

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

1,410

Actual

Start

Feb 28, 2020

Primary completion

Nov 30, 2025

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Klus Pharma Inc.Industry
Sponsor type
Industry
First posted
Nov 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: 1. Triple negative breast cancer 2. Epithelial ovarian cancer 3. Non-small cell lung cancer 4. Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma 5. Small cell lung cancer 6. HR+/ HER2-breast cancer 7. Head and neck squamous cell carcinoma 8. Endometrial carcinoma 9. Urothelial carcinoma 10. Cervical cancer

Conditions

  • Epithelial Ovarian Cancer
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Urothelial Carcinoma
  • Non-Small Cell Lung Cancer
  • Small-Cell Lung Cancer
  • Endometrial Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Breast Cancer
  • Cervical Cancer

Interventions

  • SKB264Drug

    SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Maximum Tolerated Dose (MTD) and Recommended Doses for Expansion (RDEs)Time frame: Assess up to 12 months
  2. Phase II: Objective Response Rate (ORR)Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months

Locations

109 sites in 6 countries. Site status is shown where the registry gives one.

  • Los Angeles Hematology Oncology Medical Group

    Glendale, California

  • University of California Los Angeles

    Los Angeles, California

  • Florida Cancer Specialists and Research Institute

    Sarasota, Florida

  • START MidWest

    Grand Rapids, Michigan

  • The University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Oklahoma Cancer Specialists and Research Institute, LLC

    Tulsa, Oklahoma

  • Providence Cancer Institute, Franz Clinic

    Portland, Oregon

  • Mary Crowley Cancer Research

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Sunnybrook Research Institute

    Toronto, Ontario, Canada

  • MUHC,Glen - Women's Health Research Unit

    Montreal, Quebec, Canada

  • Centro de Estudios Clínicos SAGA

    Providencia, Chile

  • Centro de Investigacion Clinica Bradford Hill

    Santiago, Chile

  • Pontificia Universidad Catolica de Chile - CICUC

    Santiago, Chile

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China

  • Anhui Cancer Hospital

    Hefei, Anhui, China

  • AnHui Provincial Cancer Hospital

    Hefei, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The First Affiliated Hospital of USTC Anhui Provincial Hospital

    Hefei, Anhui, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Beijing Chao-Yang Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Obstetrics and Gynecology Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Chinese PLA General Hospital (301 Hospital)

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Chongqing University Cancer Hosptital

    Chongqing, Chongqing Municipality, China

  • 900TH Hospital of Joint Logistics Support Force

    Fuzhou, Fujian, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Fujian Medical University Uion Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital Of Xiamen University

    Xiamen, Fujian, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Affiliated Hospital of Guangdong Medical University

    Guangzhou, Guangdong, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • Sun Yat-Sen Memorial Hospital , Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.